Chronic Infection, HIV
Conditions
Keywords
Dendritic Cell vaccination using, antiretroviral intensification, Auranofin, Histone Deacetylase Inhibitor, residual viral replication, HIV sanctuaries, HIV latency
Brief summary
It is becoming clear that a combination of interventions will be desirable to achieve HIV cure. Therefore the investigators propose a pilot proof of concept study, using combination of a number of different interventions for eradicating residual plasma viremia and decreasing HIV reservoirs. The investigators hypothesize that, (i) antiretroviral intensification using Maraviroc, and/or dolutegravir with (ii) Dendritic Cell vaccination using autologous HIV, and (iii) purging intervention using the Class III HDACs, Sirtuin-1, and (iv) decreasing the ratio of long-lived central memory (TCM)/transitional memory (TTM) CD4+ T-cells using Auranofin will provide a synergistic impact leading to a sterilizing cure of HIV infection. Results of this study may provide insightful evidence for planning the next steps using the more efficacious combination of intervention strategies towards HIV sterilizing cure.
Interventions
DRUGMaraviroc
antiretroviral intensification
DRUGDolutegravir
antiretroviral intensification
BIOLOGICALDendritic Cell Vaccine
Therapeutic vaccination
DRUGAuranofin
purging
latency disruption
Sponsors
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conselho Nacional de Desenvolvimento Científico e Tecnológico
ViiV Healthcare
Federal University of São Paulo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* \> 18 years old Documented HIV-1 infection. * Has voluntarily signed ICF. * On HAART ≥ 2 years, without changes in the 24 weeks immediately prior to screening. * HIV viral load \<50 copies/mL, and never \> 50 copies/mL on 2 consecutive occasions in the last 2 years. CD4 count nadir. * \> 350 cells/ mm3 Current CD4 count \> 500 cells/ mm3. * R5 HIV-1 at Screening as defined by proviral DNA genotropism.
Exclusion criteria
A subject will NOT be eligible for study participation if he/she meets ANY of the following criteria: * Any evidence of an active AIDS-defining condition. * Any significant acute medical illness in the past 8 weeks. * Women who are pregnant or breastfeeding. * Use of any of the following within 90 days prior to entry: systemic cytotoxic chemotherapy; investigational agents; immunomodulators (colony-stimulating factors, growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interleukins, interferons); coumadin, warfarin, or other Coumadin derivative anticoagulants. Use of an agent definitely or possibly associated with effects on QT intervals: amiodarone, arsenic trioxide, astemizole, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, probucol, procainamide, quinidine, sotalol, sparfloxacin, terfenadine, thioridazine. * Receipt of compounds with HDAC inhibitor-like activity, such as valproic acid or nicotinamide within the last 30 days. Potential participants may enroll after a 30-day washout period. * Known hypersensitivity to the components of gold salt, nicotinamide or its analogs. * Hepatitis B (HBsAg +) or Hepatitis C (HCV RNA +) infection. * Known renal insufficiency defined as calculated creatinine clearance (Cockcroft Gault formula) \<60 mL/min. * Subjects with a laboratory abnormality grade 3 or 4 with the following exceptions: pancreatic amylase, cholesterol, triglyceride, gamma glutamyl transpeptidase, bilirubin. * Any condition which, in the investigators opinion, could compromise the subject's safety or adherence to the trial protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ultrasensitive RNA Viral load, | from baseline and every 4 weeks up to 48 weeks. |
| Cell-associated HIV RNA | from baseline and every 4 weeks up to 48 weeks. |
| Episomal DNA | from baseline and every 4 weeks up to 48 weeks |
| specific HIV antibodies | from baseline and every 4 weeks up to 48 weeks |
| CD38 and HLA-DR on CD4 and CD8+ cells | from baseline and every 4 weeks up to 48 weeks |
| PBMC for env sequence evolution | from baseline and every 4 weeks up to 48 weeks |
Countries
Brazil
Outcome results
None listed